Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.

Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J.

Clin Cancer Res. 2009 Oct 1;15(19):6267-76. doi: 10.1158/1078-0432.CCR-09-1254.

2.

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.

Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD.

Cancer Immunol Immunother. 2011 Aug;60(8):1137-46. doi: 10.1007/s00262-011-1011-9. Review.

3.

Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.

Kalani AD, Jack A, Montenegro G, Degliuomini J, Wallack MK.

G Ital Dermatol Venereol. 2008 Feb;143(1):59-70. Review.

PMID:
18833052
4.

DC therapy for metastatic melanoma.

Ingram SB, O'Rourke MG.

Cytotherapy. 2004;6(2):148-53. Review. No abstract available.

PMID:
15203991
5.

CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.

Phan GQ, Weber JS, Sondak VK.

Ann Surg Oncol. 2008 Nov;15(11):3014-21. doi: 10.1245/s10434-008-0104-y. Review.

PMID:
18716842
6.

Dendritic cell vaccines in melanoma: from promise to proof?

Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ.

Crit Rev Oncol Hematol. 2008 May;66(2):118-34. doi: 10.1016/j.critrevonc.2007.12.007. Review.

PMID:
18262431
7.

Novel dendritic cell-based vaccination in late stage melanoma.

Schneble EJ, Yu X, Wagner TE, Peoples GE.

Hum Vaccin Immunother. 2014;10(11):3132-8. doi: 10.4161/hv.29110. Review.

8.

Clinical development of the anti-CTLA-4 antibody tremelimumab.

Ribas A.

Semin Oncol. 2010 Oct;37(5):450-4. doi: 10.1053/j.seminoncol.2010.09.010. Review.

PMID:
21074059
9.

The role of the CTLA4 blockade in the treatment of malignant melanoma.

Cranmer LD, Hersh E.

Cancer Invest. 2007 Oct;25(7):613-31. Review.

PMID:
18027152
10.

Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.

Morisaki T, Matsumoto K, Onishi H, Kuroki H, Baba E, Tasaki A, Kubo M, Nakamura M, Inaba S, Yamaguchi K, Tanaka M, Katano M.

Hum Cell. 2003 Dec;16(4):175-82. Review.

PMID:
15147037
11.

Strategies to overcome obstacles to successful immunotherapy of melanoma.

Pandolfi F, Cianci R, Lolli S, Dunn IS, Newton EE, Haggerty TJ, Boyle LA, Kurnick JT.

Int J Immunopathol Pharmacol. 2008 Jul-Sep;21(3):493-500. Review.

Items per page

Supplemental Content

Support Center